1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Gastrointestinal Tract Cancer-Pipeline Insights, 2017


DelveInsight’s, “ Gastrointestinal Tract Cancer-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Gastrointestinal Tract Cancer. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Gastrointestinal Tract Cancer. DelveInsight’s Report also assesses the Gastrointestinal Tract Cancer therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope

- The report provides competitivepipeline landscape of Gastrointestinal Tract Cancer
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Gastrointestinal Tract Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Gastrointestinal Tract Cancer and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Gastrointestinal Tract Cancer-Pipeline Insights, 2017
Illustrative

- Gastrointestinal Tract Cancer Overview
- Gastrointestinal Tract Cancer Pipeline Therapeutics
- Gastrointestinal Tract Cancer Therapeutics under Development by Companies
- Gastrointestinal Tract Cancer Filed and Phase III Products
- Comparative Analysis
- Gastrointestinal Tract Cancer Phase II Products
- Comparative Analysis
- Gastrointestinal Tract Cancer Phase I and IND Filed Products
- Comparative Analysis
- Gastrointestinal Tract Cancer Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Gastrointestinal Tract Cancer - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Gastrointestinal Tract Cancer - Discontinued Products
- Gastrointestinal Tract Cancer - Dormant Products
- Companies Involved in Therapeutics Development for Gastrointestinal Tract Cancer
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Gastrointestinal Tract Cancer, 2017
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2017
- Comparative Analysis Phase II Products, 2017
- Comparative Analysis Phase I and IND Filed Products, 2017
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
- Drug Candidates Profiles
- Gastrointestinal Tract Cancer Assessment by Monotherapy Products
- Gastrointestinal Tract Cancer Assessment by Combination Products
- Gastrointestinal Tract Cancer Assessment by Route of Administration
- Gastrointestinal Tract Cancer Assessment by Stage and Route of Administration
- Gastrointestinal Tract Cancer Assessment by Molecule Type
- Gastrointestinal Tract Cancer Assessment by Stage and Molecule Type
- Gastrointestinal Tract Cancer Therapeutics - Discontinued Products
- Gastrointestinal Tract Cancer Therapeutics - Dormant Products
- Products under Development by Companies, 2017


List of Figures

- Number of Products under Development for Gastrointestinal Tract Cancer, 2017
- Filed and Phase III Products, 2017
- Phase II Products, 2017
- Phase I and IND Filed Products, 2017
- Discovery and Pre-Clinical Stage Products, 2017
- Gastrointestinal Tract Cancer Assessment by Monotherapy Products
- Gastrointestinal Tract Cancer Assessment by Combination Products
- Gastrointestinal Tract Cancer Assessment by Route of Administration
- Gastrointestinal Tract Cancer Assessment by Stage and Route of Administration
- Gastrointestinal Tract Cancer Assessment by Molecule Type
- Gastrointestinal Tract Cancer Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

Epiomic Epidemiology Series: Cervical Cancer Forecast in 22 Major Markets 2016 - 2026

Epiomic Epidemiology Series: Cervical Cancer Forecast in 22 Major Markets 2016 - 2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Cervical Cancer in 22 Major Markets Cervical cancer (ICD-10 code C53, cervix uteri) is a type of cancer that occurs in the cells of ...

Non-Small Cell Lung Cancer (NSCLC) - China Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - China Drug Forecast and Market Analysis to 2025

  • $ 4995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - China Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...


Download Unlimited Documents from Trusted Public Sources

Breast Cancer Statistics in Australia - Forecast

  • January 2017
    4 pages
  • Breast Cancer  

  • Australia  

View report >

Therapy Market

  • January 2017
    19 pages
  • Therapy  

    Anticoagulant  

    Cancer  

View report >

Cancer Statistics in the US

  • January 2017
    9 pages
  • Cancer  

  • United States  

View report >

Related Market Segments :

Cancer

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.